13.01.2017 BB BIOTECH AG  CH0038389992

DGAP-Adhoc: BB Biotech AG with loss in the business year 2016


 
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Profit Warning BB Biotech AG with loss in the business year 2016 13-Jan-2017 / 18:10 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Media Release, January 13, 2017 BB Biotech AG with loss in the business year 2016 In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for the business year 2016. After a very volatile year of the biotechnology stock market BB Biotech AG closed the business year 2016 based on preliminary unaudited consolidated results with a loss of approximately CHF 802 million (CHF 653 million profit in the previous year). BB Biotech's share price increased 0.3% in CHF and 1.9% in EUR during the business year 2016. As an investment company, the results reflect the performance of the stocks it holds in its investment portfolio. The publication of the Portfolio will take place on January 20, 2017 and the complete Annual Report will be published on February 17, 2017. For further information: Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland Tanja Chicherio, Tel. +41 44 267 67 07, [email protected] www.bbbiotech.com Company profile BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science. --------------------------------------------------------------------------- 13-Jan-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: BB BIOTECH AG Schwertstrasse 6 8200 Schaffhausen Switzerland Phone: +41 52 624 08 45 Fax: +41 1 267 67 01 E-mail: [email protected] Internet: www.bbbiotech.ch ISIN: CH0038389992 WKN: A0NFN3 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX End of Announcement DGAP News Service --------------------------------------------------------------------------- 536365 13-Jan-2017 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 624,17 5,13 669,48 683,90 0,00 1,28 0,57
EBITDA1,2 588,33 -418,21 624,04 637,31 -390,46 -361,02 -222,29
EBITDA-Marge3 94,26 -8.152,24 93,21 93,19 0,00 -28.204,69
EBIT1,4 588,33 -418,21 624,04 637,31 -390,46 -361,02 -222,29
EBIT-Marge5 94,26 -8.152,24 93,21 93,19 0,00 -28.204,69 -38.998,25
Jahresüberschuss1 587,80 -418,27 622,84 637,24 -390,53 -362,83 -222,41
Netto-Marge6 94,17 -8.153,41 93,03 93,18 0,00 -28.346,09 -39.019,30
Cashflow1,7 225,26 95,66 197,69 241,97 -91,44 234,37 234,97
Ergebnis je Aktie8 10,62 -7,55 11,24 11,51 -7,05 -6,59 -4,05
Dividende8 2,85 2,68 3,20 3,32 3,67 2,88 2,58
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
BB Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0NFN3 45,800 Kaufen 2.537,32
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
32,71 5,42 6,11 115,66
KBV KCV KUV EV/EBITDA
1,06 10,80 4.451,44 -11,41
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
2,88 2,10 4,59 21.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
26.04.2024 26.07.2024 25.10.2024 16.02.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-5,62% 3,77% 0,22% -9,49%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu BB BIOTECH AG  ISIN: CH0038389992 können Sie bei EQS abrufen


Biotechnologie , A0NFN3 , BBZA , XETR:BBZA